Zofran Lawsuit Plaintiffs Use Support From Concerning Results Of Japanese Animal Studies Conducted On Drug

March 30, 2016 – – ZofranLegal.com reports on the concerning results of recent foreign animal studies which appear to support the claims of current plaintiffs involved in Zofran lawsuits by connecting exposure to the drug to a heightened risk of birth defect development in unborn animals. Only months after over 200 Zofran lawsuits were transferred and consolidated to a Boston federal court by the U.S. JPML, Zofran manufacturer and defendant GlaxoSmithKline requested that all cases be dismissed with a contentious motion filed on December 11th of 2015.

In time, the motion was dismissed by the Honorable Judge F. Dennis Saylor IV, but it will be possible for GSK to request this motion again in the future. Plaintiffs responded to GSK’s motion for dismissal by stating that there was, “reason to believe that GSK had important evidence about the defects alleged […], and the link to Zofran.” To help support this argument, plaintiffs pulled details from the results of multiple “animal teratogenicity studies” which GSK had reportedly conducted overseas in Japan. The study results seem to connect exposure to the drug to an increased risk for the development of congenital heart defects among animal’s unborn babies, which bears a striking resemblance to allegations made by the plaintiffs who indicate that their children have been born with defects after being exposed to the drug while in utero.

Plaintiffs state that the studies highlighted pregnant animals who were exposed to Zofran and who subsequently gave birth to offspring which had developed ventricular septal defects. They also claim that the studies took place after the drug had gained FDA approval for U.S. sales. Interestingly enough, however, Zofran was never approved by the FDA to treat pregnant women or tested for safety on this consumer group and their unborn babies. Instead, it was approved to treat patients suffering from nausea and vomiting episodes after undergoing chemotherapy, radiation, or anesthesia.

As these results bear a striking resemblance to the details alleged in complaints of current plaintiffs, they are understandably unsettling. For example, in one Zofran lawsuit, the mother alleges that due to the fact that she took Zofran to treat morning sickness during her first trimester of pregnancy, her baby developed Tetralogy of Fallot (a rare grouping of 4 heart defects) while in utero. The woman notes, “GSK conducted additional animal studies after the launch of Zofran in the U.S. that demonstrated increased risks of harm to fetuses in animals exposed to ondansetron [Zofran’s active ingredient] prenatally.”

Should these concerning allegations be proven to be true, GSK may face increasing public scrutiny. Plaintiffs are anxiously awaiting further results as their consolidated lawsuits progress toward litigation. As they wait, the attorneys of Monheit Law are working to help women who have taken Zofran while pregnant and who have subsequently given birth to children with defects. They want to ensure that these women will be given the opportunity to investigate their legal rights in the matter. Affected women, children, and families could be entitled to substantial compensation attained through legal action. To assist those looking to explore their legal options further, the attorneys of Monheit Law are currently offering complimentary legal consultations for qualified parties.

To request more Zofran birth defect information, or to ask questions, please contact Michael Monheit, Esq. by calling 877-620-8411.

###

Contact ZofranLegal.com:

Michael Monheit
1-877-620-8411
michael@monheit.com
1368 Barrowdale Road, Rydal, PA 19046

ReleaseID: 60008982